Skip to main content
Wegovy Pill product image

Wegovy Pill

VS
Wegovy Injection product image

Wegovy Injection

Head-to-Head Comparison

Wegovy Pill vs. Wegovy Injection

The oral Wegovy pill provides comparable weight loss to the injection in clinical trials, though the convenience of a daily pill versus a weekly injection is the main differentiator for most patients.

Key Metrics

Wegovy Pill

Wegovy Pill

Wegovy Injection

Wegovy Injection

Monthly Cost
$149–$299/mo (NovoCare)
$1,349/mo retail ($349 NovoCare)
FDA Approval

Weight Management (2025)

Weight Management (2021)

Mechanism

GLP-1 Receptor Agonist (oral)

GLP-1 Receptor Agonist (injectable)

Mean Weight Loss

~13.6–15.1% (OASIS trials)

~14.9% (STEP-1 trial)

Wegovy Pill

Key Advantages

  • No needles — daily oral tablet
  • Significantly cheaper through NovoCare ($149–$299/mo)
  • Comparable weight loss to injection in clinical trials

Wegovy Injection

Key Advantages

  • Once-weekly dosing (vs daily for pill)
  • Longest real-world data and clinical track record
  • No food/water timing restrictions

Trusted Telehealth Providers

Safety first. Access genuine medications through verified medical platforms with board-certified clinical supervision.

Henry Meds logo
TOP RATED

Henry Meds

Specializing in transparent, monthly subscription models for compounded options.

Starts At $297/mo
Visit Provider
Hims logo

Hims

Streamlined digital-first experience with competitive all-in pricing.

Starts At $297/mo
Visit Provider
Ro logo

Ro Weight Loss

White-glove concierge insurance support for brand-name GLP-1 therapy.

Starts At $145/mo*
Visit Provider

Overview

The oral Wegovy tablet launched in January 2026. It offers a needle-free option but with slightly different efficacy data and pricing than the injectable pen.

Key Differences

FactorWegovy PillWegovy Injection
FDA Approval2025 (weight management)2021 (weight management)
Monthly Cost$149–$299/mo (NovoCare)$1,349/mo retail, $349/mo NovoCare
AdministrationDaily oral tabletWeekly subcutaneous injection
Dosing25mg once dailyUp to 2.4mg once weekly
Weight Loss~13.6% (OASIS 4, 25mg)~14.9% (STEP-1, 2.4mg)
Food RestrictionsTake on empty stomach, wait 30 minNone
ManufacturerNovo NordiskNovo Nordisk

Clinical Data

Wegovy Pill (OASIS 4): 25mg oral semaglutide achieved 13.6% mean weight loss over 64 weeks. Among treatment completers, weight loss was 16.6%. 60% of participants lost ≥10% body weight.

Wegovy Injection (STEP-1): 2.4mg injectable semaglutide achieved 14.9% mean weight loss over 68 weeks. 86% achieved ≥5% weight loss, 32% achieved ≥20%.

The Pricing Advantage

The Wegovy pill’s biggest advantage is price. At $149/mo through NovoCare (starter dose), it undercuts both the injection and most compounded telehealth options. This makes it the most affordable brand-name GLP-1 currently available.

How It Compares

Frequently Asked Questions

Is the Wegovy pill as effective as the injection?

Clinical data shows closely comparable weight-loss outcomes. In OASIS 4, the 25 mg oral semaglutide dose achieved 13.6% mean weight loss over 64 weeks; among treatment completers, that rose to 16.6%. The STEP-1 injectable Wegovy trial showed 14.9% mean weight loss over 68 weeks, with 32% of patients losing ≥20% of body weight. The ~1.3% gap in mean weight loss between formulations may be attributable to trial design differences rather than a true efficacy difference. In OASIS 1, the higher 50 mg oral dose showed 15.1% weight loss — essentially matching the injectable across different dose levels. Semaglutide blood levels achieved with the oral formulation are pharmacokinetically comparable to the injection at therapeutic doses. Real-world adherence data for the oral Wegovy Pill is still emerging given its early 2026 launch, but early reports suggest strong patient satisfaction with the pill format. For most patients, the evidence supports treating the two formulations as clinically equivalent — the choice between them is about format preference, convenience, and cost.

Why is the Wegovy pill so much cheaper?

Novo Nordisk priced the oral Wegovy Pill aggressively through NovoCare for strategic market reasons: to compete directly with compounded semaglutide telehealth providers (which had captured a significant patient population at $150–350/month during the shortage era), to compete with Eli Lilly’s Foundayo ($149/month) and Zepbound ($299–449/month through LillyDirect), and to drive rapid adoption of the oral formulation before competitors could establish a dominant position. The $149/month NovoCare starter price is essentially at or near compounded semaglutide pricing — eliminating the cost advantage that had driven patients to compounding pharmacies. This pricing strategy also locks in the Novo Nordisk relationship with patients who might otherwise switch to Eli Lilly products. The economics work for Novo Nordisk because oral formulations have lower manufacturing costs than injectable pens at scale, and market share gains justify the aggressive entry pricing.

Do I need to take it on an empty stomach?

Yes — and this requirement is non-negotiable for the Wegovy Pill to work properly. Take it first thing in the morning on an empty stomach with no more than 4 oz of plain water, then wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications. The oral semaglutide formulation relies on a SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer that temporarily changes the stomach’s pH environment, allowing the semaglutide peptide to pass through the gastric mucosa. Food, other liquids, or competing medications taken at the same time disrupt this process, potentially reducing bioavailability by 50% or more and substantially undermining the medication’s effectiveness. In OASIS clinical trials, this fasting protocol was enforced rigorously. Patients who consistently skip the fasting window will see significantly reduced outcomes compared to trial data. If this morning routine is incompatible with your lifestyle, Foundayo (orforglipron) is an oral GLP-1 alternative with no food or timing restrictions, available at comparable pricing.

Keep Reading

Frequently Asked Questions

Is the Wegovy pill as effective as the injection?
Clinical data shows closely comparable weight-loss outcomes. In OASIS 4, the 25 mg oral semaglutide dose achieved 13.6% mean weight loss over 64 weeks; among treatment completers, that rose to 16.6%. The STEP-1 injectable Wegovy trial showed 14.9% mean weight loss over 68 weeks, with 32% of patients losing ≥20% of body weight. The ~1.3% gap in mean weight loss between formulations may be attributable to trial design differences rather than a true efficacy difference. In OASIS 1, the higher 50 mg oral dose showed 15.1% weight loss — essentially matching the injectable across different dose levels. Semaglutide blood levels achieved with the oral formulation are pharmacokinetically comparable to the injection at therapeutic doses. Real-world adherence data for the oral Wegovy Pill is still emerging given its early 2026 launch, but early reports suggest strong patient satisfaction with the pill format. For most patients, the evidence supports treating the two formulations as clinically equivalent — the choice between them is about format preference, convenience, and cost.
Why is the Wegovy pill so much cheaper?
Novo Nordisk priced the oral Wegovy Pill aggressively through NovoCare for strategic market reasons: to compete directly with compounded semaglutide telehealth providers (which had captured a significant patient population at $150–350/month during the shortage era), to compete with Eli Lilly's Foundayo ($149/month) and Zepbound ($299–449/month through LillyDirect), and to drive rapid adoption of the oral formulation before competitors could establish a dominant position. The $149/month NovoCare starter price is essentially at or near compounded semaglutide pricing — eliminating the cost advantage that had driven patients to compounding pharmacies. This pricing strategy also locks in the Novo Nordisk relationship with patients who might otherwise switch to Eli Lilly products. The economics work for Novo Nordisk because oral formulations have lower manufacturing costs than injectable pens at scale, and market share gains justify the aggressive entry pricing.
Do I need to take it on an empty stomach?
Yes — and this requirement is non-negotiable for the Wegovy Pill to work properly. Take it first thing in the morning on an empty stomach with no more than 4 oz of plain water, then wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications. The oral semaglutide formulation relies on a SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer that temporarily changes the stomach's pH environment, allowing the semaglutide peptide to pass through the gastric mucosa. Food, other liquids, or competing medications taken at the same time disrupt this process, potentially reducing bioavailability by 50% or more and substantially undermining the medication's effectiveness. In OASIS clinical trials, this fasting protocol was enforced rigorously. Patients who consistently skip the fasting window will see significantly reduced outcomes compared to trial data. If this morning routine is incompatible with your lifestyle, Foundayo (orforglipron) is an oral GLP-1 alternative with no food or timing restrictions, available at comparable pricing.
Affiliate Disclosure: GLP-1 Price Guide may receive a commission if you choose to utilize the services or tools linked on this page. Our research team maintains strict editorial independence to ensure objective pricing data.